Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it granted inducement equity awards on March 15, 2026 to seven new non-executive employees under its 2025 Inducement Plan.

The company granted an aggregate of 1,739 time-based restricted stock units, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4). All RSUs vest in four equal annual installments on each of the first through fourth anniversaries, subject to continued employment.

News Market Reaction – MDGL

-2.88%

-2.88% Session close to close

In the Mar 20 session, MDGL declined 2.88%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a routine HR and compensation event, granting 1,739 time-based RSUs to 7 n...

Analysis

This announcement details a routine HR and compensation event, granting 1,739 time-based RSUs to 7 new non-executive employees under the 2025 Inducement Plan. Similar inducement awards in recent months have coincided with only modest share-price moves, while larger fundamental catalysts such as the $321.1M Q4 revenue report and the siRNA licensing deal have driven more notable reactions. Investors may monitor future operational milestones and financing or licensing updates for more material impacts.

Key Figures

New employees: 7 employees Inducement RSUs: 1,739 RSUs Vesting schedule: 4 annual installments +1 more

4 metrics

New employees 7 employees Non-executive hires receiving inducement awards on March 15, 2026

Inducement RSUs 1,739 RSUs Aggregate time-based restricted stock units granted under 2025 Inducement Plan

Vesting schedule 4 annual installments RSUs vest yearly from first through fourth anniversaries of grant date

Current share price $442.00 Pre-news market price vs 52-week range $265.00–$615.00

Historical Context

5 past events · Latest: Mar 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 05	Inducement equity awards	Neutral	-1.5%	Grant of options and RSUs to new non-executive employees under inducement plan.
Feb 24	Conference participation	Neutral	+0.5%	Announcement of participation in TD Cowen healthcare conference with webcast details.
Feb 19	Earnings and update	Positive	-11.1%	Reported strong 2025 Rezdiffra sales, cash position, loans and licensing progress.
Feb 17	Inducement equity awards	Neutral	+0.9%	RSU grants to new employees under 2025 Inducement Plan with four-year vesting.
Feb 11	Licensing agreement	Positive	+0.5%	Exclusive license for six pre-clinical siRNA MASH programs with upfront and milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Routine HR and corporate news has typically led to modest moves, while a recent earnings release with strong operational metrics saw a notably negative price reaction.

Recent Company History

Over the past months, Madrigal has mixed routine corporate updates with major strategic milestones. Repeated inducement award announcements on Feb 15, 2026 and Mar 1, 2026 involved time‑based RSUs and options, generally prompting only small price moves. In contrast, the Feb 19, 2026 earnings report highlighted $321.1M Q4 and $958.4M 2025 net sales plus $988.6M in cash, yet the stock fell 11.11%. A US$60M upfront siRNA licensing deal on Feb 11, 2026 had a modest positive impact.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), equity inducement awards, inducement plan

4 terms

restricted stock units financial

"The new employees received, in the aggregate, 1,739 time-based restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity inducement awards financial

"it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

inducement plan financial

"as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan."

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 1,739 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What did Madrigal (MDGL) announce on March 19, 2026 about inducement awards?

Madrigal announced it granted inducement equity awards to seven new non-executive employees on March 15, 2026. According to Madrigal, the awards total 1,739 RSUs under the company's 2025 Inducement Plan and were approved under Nasdaq Listing Rule 5635(c)(4).

How many restricted stock units did Madrigal (MDGL) grant to new employees on March 15, 2026?

Madrigal granted an aggregate of 1,739 time-based restricted stock units to new employees. According to Madrigal, the RSUs were issued as inducement awards to attract seven non-executive hires under the 2025 Inducement Plan.

What is the vesting schedule for the MDGL inducement RSUs granted March 15, 2026?

The RSUs vest in four equal installments on each of the first through fourth anniversaries of the grant date. According to Madrigal, vesting is subject to each employee's continued employment on the applicable vesting dates.

Were the Madrigal (MDGL) inducement awards approved under Nasdaq rules?

Yes. The awards were approved by Madrigal's independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4). According to Madrigal, the approval satisfied the Nasdaq requirement for inducement awards for newly hired employees.

Do Madrigal's March 2026 RSU grants immediately vest or require continued employment?

The RSU grants do not vest immediately; they require continued employment to vest. According to Madrigal, all awards vest in four equal annual installments, contingent on each employee remaining employed on each vesting date.